Drug profile · INN
idecabtagene vicleucel
ABECMA
idecabtagene vicleucel (ABECMA) is a tumor necrosis factor receptor superfamily member 17 binding agent.
Drug details — idecabtagene vicleucel
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
idecabtagene vicleucel (ABECMA) is a tumor necrosis factor receptor superfamily member 17 binding agent.
Key facts
Mechanism of action
Tumor necrosis factor receptor superfamily member 17 binding agent
Primary target: Tumor necrosis factor receptor superfamily member 17
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
CAR-T Cell Therapy Japan: Regulatory Insights & Clinical Trial Landscape
This article delves into CAR-T cell therapy in Japan, highlighting regulatory frameworks and the evolving clinical trial landscape for hematologic malignancies.
CAR-T Access EU Policy: Impact of Cross-Border Healthcare on Advanced Therapies
This article examines the implications of cross-border healthcare policies on CAR-T therapies for cancer, highlighting access challenges and opportunities in the EU.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is idecabtagene vicleucel?
idecabtagene vicleucel (ABECMA) is a tumor necrosis factor receptor superfamily member 17 binding agent.
What is the brand name for idecabtagene vicleucel?
ABECMA is a marketed brand name for idecabtagene vicleucel. Check FDA Drugs@FDA for the current US label holder and prescribing information.